The biosimilars reach the US market as the US insulin space has seen seismic changes in the last few years, with a clamour of ...

The US Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart), ...

Merilog’s approval comes as the insulin space has over the past year suffered several setbacks, including strong calls for ...

The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...

Sanofi (NASDAQ:SNY) has received FDA approval for Merilog, a biosimilar of Novo Nordisk's (NVO) rapid-acting insulin product NovoLog, for the improvement of glycemic control in adults and children ...

Novo Nordisk A/S today announced 2024 earnings ... A surprise was the performance of the insulin division — long acting insulin revenues were up 28%, to $2.7bn, premix insulin up 13%, to ...

Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth ... Instead, the beat came from insulin, thanks to favorable U.S. rebate adjustments, analysts said.

The global Diabetes Drugs Market size was valued at USD 84.65 billion in 2024 and is expected to be worth around USD 177.74 ...

The Business Research Company Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

The Business Research Company Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

Novo Nordisk is also pairing the long-acting insulin with its once-weekly GLP-1 agonist semaglutide in the COMBINE trials programme, which is due to complete in 2024, is also working on a glucose ...